These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21062929)

  • 41. A Comprehensive Program for the Enhancement of Accrual to Clinical Trials.
    Porter M; Ramaswamy B; Beisler K; Neki P; Single N; Thomas J; Hofacker J; Caligiuri M; Carson WE
    Ann Surg Oncol; 2016 Jul; 23(7):2146-52. PubMed ID: 26790668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estimating the rate and reasons of clinical trial failure in urologic oncology.
    Stensland KD; DePorto K; Ryan J; Kaffenberger S; Reinstatler LS; Galsky M; Canes D; Skolarus TA; Moinzadeh A
    Urol Oncol; 2021 Mar; 39(3):154-160. PubMed ID: 33257221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and Validation of a Clinical Trial Accrual Predictive Regression Model at a Single NCI-Designated Comprehensive Cancer Center.
    Tate WR; Cranmer LD
    J Natl Compr Canc Netw; 2016 May; 14(5):561-9. PubMed ID: 27160234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade.
    Peters GW; Tao W; Wei W; Miccio JA; Jethwa KR; Cecchini M; Johung KL
    Oncologist; 2021 Aug; 26(8):660-667. PubMed ID: 33728733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Organizational and physician factors associated with patient enrollment in cancer clinical trials.
    Jacobs SR; Weiner BJ; Reeve BB; Weinberger M; Minasian LM; Good MJ
    Clin Trials; 2014 Oct; 11(5):565-75. PubMed ID: 24902923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020).
    Jenei K; Haslam A; Olivier T; Miljkovíc M; Prasad V
    BMJ Open; 2022 Oct; 12(10):e064458. PubMed ID: 36207035
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.
    Mitchell AP; Hirsch BR; Abernethy AP
    Trials; 2014 Mar; 15():92. PubMed ID: 24661848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic Locations.
    Ruther NR; Mathiason MA; Wee SK; Emmel AE; Go RS
    Am J Clin Oncol; 2015 Dec; 38(6):575-82. PubMed ID: 24517955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Accrual to Trans-Tasman Radiation Oncology Group-sponsored trials 2010-2012.
    Christie DR
    J Med Imaging Radiat Oncol; 2013 Aug; 57(4):499-502. PubMed ID: 23870351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NCI-Clinical Trial Accrual in a Community Network Affiliated with a Designated Cancer Center.
    Kim DJ; Otap D; Ruel N; Gupta N; Khan N; Dorff T
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32599694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual.
    St Germain D; Denicoff AM; Dimond EP; Carrigan A; Enos RA; Gonzalez MM; Wilkinson K; Mathiason MA; Duggan B; Einolf S; McCaskill-Stevens W; Bryant DM; Thompson MA; Grubbs SS; Go RS
    J Oncol Pract; 2014 Mar; 10(2):e73-80. PubMed ID: 24424313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
    Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
    J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.
    Jacobs SR; Weiner BJ; Minasian LM; Good MJ
    Contemp Clin Trials; 2013 Mar; 34(2):320-5. PubMed ID: 23295315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
    Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
    Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.
    Bakouny Z; Labaki C; Bhalla S; Schmidt AL; Steinharter JA; Cocco J; Tremblay DA; Awad MM; Kessler A; Haddad RI; Evans M; Busser F; Wotman M; Curran CR; Zimmerman BS; Bouchard G; Jun T; Nuzzo PV; Qin Q; Hirsch L; Feld J; Kelleher KM; Seidman D; Huang H; Anderson-Keightly HM; El Zarif T; Alaiwi SA; Champagne C; Rosenbloom TD; Stewart PS; Johnson BE; Trinh Q; Tolaney SM; Galsky MD; Choueiri TK; Doroshow DB
    Ann Oncol; 2022 Aug; 33(8):836-844. PubMed ID: 35715285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Feasibility of a Centralized Clinical Trials Coverage Analysis: A Joint Initiative of the American Society of Clinical Oncology and the National Cancer Institute.
    Szczepanek CM; Hurley P; Good MJ; Denicoff A; Willenberg K; Dawson C; Kurbegov D
    J Oncol Pract; 2017 Jun; 13(6):395-400. PubMed ID: 28481681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.
    Khunger M; Rakshit S; Hernandez AV; Pasupuleti V; Glass K; Galsky MD; Grivas P
    Oncologist; 2018 Dec; 23(12):1494-1499. PubMed ID: 30068783
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
    Schroen AT; Petroni GR; Wang H; Thielen MJ; Gray R; Benedetti J; Wang XF; Sargent DJ; Wickerham DL; Cronin W; Djulbegovic B; Slingluff CL
    Clin Cancer Res; 2012 Jan; 18(1):256-62. PubMed ID: 21976533
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incremental treatment costs in national cancer institute-sponsored clinical trials.
    Goldman DP; Berry SH; McCabe MS; Kilgore ML; Potosky AL; Schoenbaum ML; Schonlau M; Weeks JC; Kaplan R; Escarce JJ
    JAMA; 2003 Jun; 289(22):2970-7. PubMed ID: 12799405
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program.
    Kaluzny AD; Lacey LM; Warnecke R; Hynes DM; Morrissey J; Ford L; Sondik E
    Health Serv Res; 1993 Jun; 28(2):159-82. PubMed ID: 8514498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.